English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Patent

Improved preparation of vaccines against Streptococcus pneumoniae type 3

MPS-Authors
/persons/resource/persons121849

Seeberger,  Peter H.
Peter H. Seeberger, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121719

Pereira,  Claney Lebev
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons188901

Parameswarappa,  Sharavathi Guddehalli
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons200006

Calow,  Adam D. J.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons211351

Menova,  Petra
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons185292

Baek,  Ju Yuel
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)

Patent.pdf
(Publisher version), 3MB

Supplementary Material (public)
There is no public supplementary material available
Citation

Seeberger, P. H., Pereira, C. L., Parameswarappa, S. G., Calow, A. D. J., Menova, P., & Baek, J. Y.(2017). Improved preparation of vaccines against Streptococcus pneumoniae type 3.


Cite as: https://hdl.handle.net/11858/00-001M-0000-002E-1866-2
Abstract
The present invention relates to the preparation of a synthetic tetrasaccharide representing part of the repeating unit of the Streptococcus pneumoniae type 3 capsular polysaccharide as well as conjugates thereof. Said conjugates are particularly useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae type 3. The disclosed synthetic method has the huge advantages over the state of the art synthetic methods that intermediate products are crystalline, coupling reaction yields are higher, less reaction steps are required and purification of intermediate products is easier.